Menu
Menu
BOSTON, United States and ROLLE, Switzerland, November 4, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results 2025 Financial Outlook "Q3 was an excellent quarter for SOPHiA GENETICS, with revenue growth accelerating for a third […]
We are thrilled to share that TomaLab, one of the largest genetic laboratories in Italy, has expanded their partnership with SOPHiA GENETICS, adding exome, solid tumor and hereditary cancer applications to gain insights across multiple cancers and inherited disorders. By combining TomaLab’s deep expertise with our platform’s advanced analytics, they are now poised to deliver […]
BOSTON, United States and ROLLE, Switzerland, October 21, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2025 before U.S. markets open on Tuesday, November 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its […]
ROLLE AND TOKYO, October 16, 2025 – A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company pioneering data-driven medicine, today announced at ESMO a strategic agreement to bring cutting-edge liquid biopsy genomic testing to the Japanese population. The companies will also partner to commercialize a liquid biopsy […]
Welcome to our global network Unilabs Netherlands! Unilabs Netherlands is one of the country’s leading diagnostic healthcare providers, offering a comprehensive range of laboratory, imaging, pathology and specialized services through a large network of labs and sample‐collection points to make reliable diagnostics accessible to patients and providers. They will leverage SOPHiA DDM™ to analyze inherited […]
🚀 We are proud to continue our expansion in the Middle East through our collaboration with National Reference Laboratory (NRL), a leader in pathology and one of the largest CAP-accredited laboratory networks in the region. This partnership reflects a shared commitment to advancing data-driven cancer care and expanding access to genomic insights across the UAE. […]
SALT LAKE CITY AND BOSTON, MA - September 23, 2025 – Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) […]
BOSTON, MA - September 22, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an […]
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
